Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety.

Détails

Ressource 1Télécharger: 34885044_BIB_1AE49D79BF32.pdf (1919.47 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_1AE49D79BF32
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety.
Périodique
Cancers
Auteur⸱e⸱s
Delage J.A., Gnesin S., Prior J.O., Barbet J., Le Saëc P., Marionneau-Lambot S., Gouard S., Chérel M., Bourgeois M., Schaefer N., Viertl D., Fierle J.K., Dunn S.M., Faivre-Chauvet A.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Statut éditorial
Publié
Date de publication
25/11/2021
Peer-reviewed
Oui
Volume
13
Numéro
23
Pages
5936
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
1C1m-Fc, a promising anti-TEM-1 DOTA conjugate, was labeled with <sup>64</sup> Cu to target cancer cells for PET imaging and predicting the efficacy and safety of a previously studied [ <sup>177</sup> Lu]Lu-1C1m-Fc companion therapy. DOTA-conjugated 1C1m-Fc was characterized by mass spectrometry, thin layer chromatography and immunoreactivity assessment. PET/CT and biodistribution studies were performed in human neuroblastoma xenografted mice. Absorbed doses were assessed from biodistribution results and extrapolated to <sup>177</sup> Lu based on the [ <sup>64</sup> Cu]Cu-1C1m-Fc data. The immunoreactivity was ≥ 70% after 48 h of incubation in serum, and the specificity of [ <sup>64</sup> Cu]Cu-1C1m-Fc for the target was validated. High-resolution PET/CT images were obtained, with the best tumor-to-organ ratios reached at 24 or 48 h and correlated with results of the biodistribution study. Healthy organs receiving the highest doses were the liver, the kidneys and the uterus. [ <sup>64</sup> Cu]Cu-1C1m-Fc could be of interest to give an indication of <sup>177</sup> Lu dosimetry for parenchymal organs. In the uterus and the tumor, characterized by specific TEM-1 expression, the <sup>177</sup> Lu-extrapolated absorbed doses are overestimated because of the lack of later measurement time points. Nevertheless, 1C1m-Fc radiolabeled with <sup>64</sup> Cu for imaging would appear as an interesting radionuclide companion for therapeutic application with [ <sup>177</sup> Lu]Lu-1C1m-Fc.
Mots-clé
DOTA conjugation, Lutetium-177, PET imaging, copper-64, dosimetry, theranostic, tumor endothelial marker 1
Pubmed
Web of science
Open Access
Oui
Création de la notice
15/12/2021 17:20
Dernière modification de la notice
23/11/2022 7:08
Données d'usage